{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:46:43Z","timestamp":1790016403078,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID,","doi-asserted-by":"publisher","award":["1U01AI074512-1"],"award-info":[{"award-number":["1U01AI074512-1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.virol.2016.02.024","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T20:45:50Z","timestamp":1458593150000},"page":"197-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A cationic liposome\u2013DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets"],"prefix":"10.1016","volume":"492","author":[{"given":"Feng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Fairman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence M.","family":"Tumpey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2016.02.024_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1750-2659.2008.00054.x","article-title":"A vaccine manufacturer\u2019s approach to address medical needs related to seasonal and pandemic influenza viruses","volume":"2","author":"Baras","year":"2008","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.virol.2016.02.024_bib2","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1371\/journal.pone.0001401","article-title":"Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine","volume":"3","author":"Baras","year":"2008","journal-title":"PloS ONE"},{"key":"10.1016\/j.virol.2016.02.024_bib3","doi-asserted-by":"crossref","first-page":"234ra255","DOI":"10.1126\/scitranslmed.3008761","article-title":"A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults","volume":"6","author":"Bart","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2016.02.024_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 vaccines in humans","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2016.02.024_bib5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA:\u00a0J.\u00a0Am. Med. Assoc."},{"key":"10.1016\/j.virol.2016.02.024_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/CVI.00370-08","article-title":"Potent adjuvant activity of cationic liposome\u2013DNA complexes for genital herpes vaccines","volume":"16","author":"Bernstein","year":"2009","journal-title":"Clin. Vaccine Immunol.\u00a0\u2013 CVI"},{"key":"10.1016\/j.virol.2016.02.024_bib7","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/CVI.00373-12","article-title":"Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A\/H5N1 prepandemic influenza vaccine in adult and elderly subjects","volume":"19","author":"Bihari","year":"2012","journal-title":"Clin. Vaccine Immunol.\u00a0\u2013 CVI"},{"key":"10.1016\/j.virol.2016.02.024_bib8","series-title":"Estimates of Deaths Associated with Seasonal Influenza \u2013 United States, 1976\u20132007","first-page":"1057","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010"},{"key":"10.1016\/j.virol.2016.02.024_bib9","first-page":"141","article-title":"A novel vaccine adjuvant for recombinant flu antigens","volume":"37","author":"Chang","year":"2009","journal-title":"Biol. \u2013 J. Int. Assoc. Biol. Stand."},{"key":"10.1016\/j.virol.2016.02.024_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.vaccine.2011.10.103","article-title":"Cationic liposome\u2013DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice","volume":"30","author":"Dong","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2016.02.024_bib11","series-title":"Early Estimates of Seasonal Influenza Vaccine Effectiveness \u2013 United States, January 2015","first-page":"10","volume":"64","author":"Flannery","year":"2015"},{"key":"10.1016\/j.virol.2016.02.024_bib12","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2016.02.024_bib13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.virol.2016.02.024_bib14","doi-asserted-by":"crossref","first-page":"12691","DOI":"10.1128\/JVI.00769-10","article-title":"Cationic lipid\/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity","volume":"84","author":"Hong","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.02.024_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.virol.2016.02.024_bib16","series-title":"Outbreaks of Avian Influenza A (H5N2), (H5N8), and (H5N1) Among Birds \u2013 United States, December 2014\u2013January 2015","first-page":"111","volume":"64","author":"Jhung","year":"2015"},{"key":"10.1016\/j.virol.2016.02.024_bib17","doi-asserted-by":"crossref","first-page":"e95496","DOI":"10.1371\/journal.pone.0095496","article-title":"Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization","volume":"9","author":"Khurana","year":"2014","journal-title":"PloS ONE"},{"issue":"Suppl 1","key":"10.1016\/j.virol.2016.02.024_bib18","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0264-410X(99)00104-8","article-title":"Surveillance and impact of influenza in the United States","volume":"17","author":"Klimov","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2016.02.024_bib19","doi-asserted-by":"crossref","first-page":"e66312","DOI":"10.1371\/journal.pone.0066312","article-title":"Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005\u20132011","volume":"8","author":"Kostova","year":"2013","journal-title":"PloS ONE"},{"key":"10.1016\/j.virol.2016.02.024_bib20","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1016\/j.vaccine.2009.04.054","article-title":"Cationic lipid\/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection","volume":"27","author":"Lay","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2016.02.024_bib21","doi-asserted-by":"crossref","first-page":"e20641","DOI":"10.1371\/journal.pone.0020641","article-title":"Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret","volume":"6","author":"Layton","year":"2011","journal-title":"PloS ONE"},{"key":"10.1016\/j.virol.2016.02.024_bib22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1517\/14712590903066695","article-title":"Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data","volume":"9","author":"Leroux-Roels","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.virol.2016.02.024_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/erv.09.15","article-title":"Current status and progress of prepandemic and pandemic influenza vaccine development","volume":"8","author":"Leroux-Roels","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virol.2016.02.024_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","article-title":"Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2016.02.024_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of protection against influenza infection in humans--on the path to a universal vaccine?","volume":"25","author":"Li","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.virol.2016.02.024_bib26","doi-asserted-by":"crossref","first-page":"e71765","DOI":"10.1371\/journal.pone.0071765","article-title":"Seroprevalence of antibodies to highly pathogenic avian influenza A (H5N1) virus among close contacts exposed to H5N1 cases, China, 2005\u20132008","volume":"8","author":"Liao","year":"2013","journal-title":"PloS ONE"},{"key":"10.1016\/j.virol.2016.02.024_bib27","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/JVI.73.7.5903-5911.1999","article-title":"A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans","volume":"73","author":"Lu","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.02.024_bib28","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.1128\/JVI.79.18.11788-11800.2005","article-title":"Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals","volume":"79","author":"Maines","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.02.024_bib29","article-title":"Interim estimates of 2014\/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015","volume":"20","author":"McNeil","year":"2015","journal-title":"Euro Surveill.\u00a0\u2013 Bull. Eur. Mal. Transm. \u2013 Europ. Commun. Dis. Bull."},{"key":"10.1016\/j.virol.2016.02.024_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1086\/314952","article-title":"Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection","volume":"180","author":"Moran","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2016.02.024_bib31","doi-asserted-by":"crossref","first-page":"e73200","DOI":"10.1371\/journal.pone.0073200","article-title":"Seroprevalence of antibodies against highly pathogenic avian influenza A (H5N1) virus among poultry workers in Bangladesh, 2009","volume":"8","author":"Nasreen","year":"2013","journal-title":"PloS ONE"},{"key":"10.1016\/j.virol.2016.02.024_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/oxfordjournals.bmb.a071545","article-title":"Determinants of immunity to influenza infection in man","volume":"35","author":"Potter","year":"1979","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.virol.2016.02.024_bib33","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/j.vaccine.2010.03.068","article-title":"Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature","volume":"28","author":"Prieto-Lara","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2016.02.024_bib34","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1016\/j.vaccine.2008.04.071","article-title":"Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants","volume":"26","author":"Radosevic","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2016.02.024_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/irv.12324","article-title":"Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013\u20132014","volume":"9","author":"Smith","year":"2015","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.virol.2016.02.024_bib37","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2016.02.024_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virusres.2004.02.019","article-title":"Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A\/Duck\/Singapore\/97 vaccine","volume":"103","author":"Stephenson","year":"2004","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2016.02.024_bib39","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1371\/journal.ppat.0030040","article-title":"H5N1 viruses and vaccines","volume":"3","author":"Subbarao","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2016.02.024_bib40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.279.5349.393","article-title":"Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness","volume":"279","author":"Subbarao","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.virol.2016.02.024_bib41","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.1241146","article-title":"Diversity among memory B cells: origin, consequences, and utility","volume":"341","author":"Tarlinton","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.virol.2016.02.024_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3201\/eid1201.051237","article-title":"Cell-mediated protection in influenza infection","volume":"12","author":"Thomas","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2016.02.024_bib43","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.292.11.1333","article-title":"Influenza-associated hospitalizations in the United States","volume":"292","author":"Thompson","year":"2004","journal-title":"JAMA: J. Am. Med. Assoc."},{"key":"10.1016\/j.virol.2016.02.024_bib44","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2016.02.024_bib45","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.virol.2016.02.024_bib46","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1111\/irv.12077","article-title":"Brief literature review for the WHO global influenza research agenda \u2013 highly pathogenic avian influenza H5N1 risk in humans","volume":"7","author":"Van Kerkhove","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.virol.2016.02.024_bib47","unstructured":"WHO, Antigenic and genetic characteristics of zoonotic influenza viruses and candidate vaccine viruses developed for potential use in human vaccines. Available at: \u3008http:\/\/www.who.int\/influenza\/vaccines\/virus\/characteristics_virus_vaccines\/en\/\u3009."},{"key":"10.1016\/j.virol.2016.02.024_bib48","series-title":"Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza","author":"WHO","year":"2011"},{"key":"10.1016\/j.virol.2016.02.024_bib49","series-title":"Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO","author":"WHO","year":"2015"},{"key":"10.1016\/j.virol.2016.02.024_bib50","first-page":"349","article-title":"Human cases of influenza at the human-animal interface, January 2014\u2013April 2015","volume":"90","author":"WHO","year":"2015","journal-title":"Wkly. Epidemiol. Rec.\/Health Sect. Secr. Leag. Nations"},{"key":"10.1016\/j.virol.2016.02.024_bib51","unstructured":"WHO, 2012. H5N1 avian influenza: Timeline of major events."},{"key":"10.1016\/j.virol.2016.02.024_bib52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2016.02.024_bib53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra0707279","article-title":"Update on avian influenza A (H5N1) virus infection in humans","volume":"358","author":"Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2016.02.024_bib54","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.4049\/jimmunol.176.12.7335","article-title":"Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes","volume":"176","author":"Zaks","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2016.02.024_bib55","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1128\/JVI.76.9.4420-4429.2002","article-title":"Pathogenesis of avian influenza A (H5N1) viruses in ferrets","volume":"76","author":"Zitzow","year":"2002","journal-title":"J. Virol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682216300198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682216300198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:37:03Z","timestamp":1758587823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682216300198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":54,"alternative-id":["S0042682216300198"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2016.02.024","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cationic liposome\u2013DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2016.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}